Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?

被引：4

作者：

Duma, Narjust ^{[1
]}

Gast, Kelly C. ^{[2
]}

Choong, Grace M. ^{[2
]}

Leon-Ferre, Roberto A. ^{[1
]}

O'Sullivan, Ciara C. ^{[1
]}

机构：

[1] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Internal Med, Rochester, MN 55905 USA

来源：

CURRENT ONCOLOGY REPORTS | 2018年 / 20卷 / 08期

关键词：

Poly(ADP-ribose) polymerases; PARP inhibitors; Triple-negative breast cancer; BRCA1/2; mutations; BRCAness; BRCA MUTATION CARRIERS; PHASE-I TRIAL; POLY(ADP-RIBOSE) POLYMERASE; DNA-DAMAGE; OVARIAN-CARCINOMA; DOSE-ESCALATION; MUTANT-CELLS; OLAPARIB; RESISTANCE; REPAIR;

D O I：

10.1007/s11912-018-0709-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To provide an overview of the clinical development of poly(ADP-ribose) polymerase inhibitors (PARPi) in breast cancer to date and to review existing challenges and future research directions. We summarize the clinical development of PARPi in breast cancer from bench to bedside, and discuss the results of recent phase 3 trials in patients with metastatic breast cancer (MBC) and germline mutations in BRCA1/2 (gBRCAm). We will also provide an update regarding mechanisms of action and resistance to PARPi, and review clinical trials of PARPi as monotherapy or in combination regimens. PARPi are a novel treatment approach in persons with gBRCA1/2m-associated MBC. Going forward, the clinical applicability of these compounds outside the gBRCAm setting will be studied in greater detail. The identification of accurate predictive biomarkers of response is a research priority.

引用

页数：12

共 72 条

[51] Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action [J].

Pommier, Yves ;

O'Connor, Mark J. ;

de Bono, Johann .

SCIENCE TRANSLATIONAL MEDICINE, 2016, 8 (362)

[52] Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation [J].

Robson, Mark ;

Im, Seock-Ah ;

Senkus, Elzbieta ;

Xu, Binghe ;

Domchek, Susan M. ;

Masuda, Norikazu ;

Delaloge, Suzette ;

Li, Wei ;

Tung, Nadine ;

Armstrong, Anne ;

Wu, Wenting ;

Goessl, Carsten ;

Runswick, Sarah ;

Conte, Pierfranco .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (06) :523-533

[53] Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer [J].

Rodler, Eve T. ;

Kurland, Brenda F. ;

Griffin, Melissa ;

Gralow, Julie R. ;

Porter, Peggy ;

Yeh, Rosa F. ;

Gadi, Vijayakrishna K. ;

Guenthoer, Jamie ;

Beumer, Jan H. ;

Korde, Larissa ;

Strychor, Sandra ;

Kiesel, Brian F. ;

Linden, Hannah M. ;

Thompson, John A. ;

Swisher, Elizabeth ;

Chai, Xiaoyu ;

Shepherd, Stacie ;

Giranda, Vincent ;

Specht, Jennifer M. .

CLINICAL CANCER RESEARCH, 2016, 22 (12) :2855-2864

[54] PARP inhibition: PARP1 and beyond [J].

Rouleau, Michele ;

Patel, Anand ;

Hendzel, Michael J. ;

Kaufmann, Scott H. ;

Poirier, Guy G. .

NATURE REVIEWS CANCER, 2010, 10 (04) :293-301

[55] The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial [J].

Sandhu, Shahneen K. ;

Schelman, William R. ;

Wilding, George ;

Moreno, Victor ;

Baird, Richard D. ;

Miranda, Susana ;

Hylands, Lucy ;

Riisnaes, Ruth ;

Forster, Martin ;

Omlin, Aurelius ;

Kreischer, Nathan ;

Thway, Khin ;

Gevensleben, Heidrun ;

Sun, Linda ;

Loughney, John ;

Chatterjee, Manash ;

Toniatti, Carlo ;

Carpenter, Christopher L. ;

Iannone, Robert ;

Kaye, Stan B. ;

de Bono, Johann S. ;

Wenham, Robert M. .

LANCET ONCOLOGY, 2013, 14 (09) :882-892

[56] Trapping Poly(ADP-Ribose) Polymerase [J].

Shen, Yuqiao ;

Aoyagi-Scharber, Mika ;

Wang, Bing .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2015, 353 (03) :446-457

[57] Downfall of Iniparib: A PARP Inhibitor That Doesn't Inhibit PARP After All [J].

Sinha, Gunjan .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (01)

[58] An update on PARP inhibitors-moving to the adjuvant setting [J].

Sonnenblick, Amir ;

de Azambuja, Evandro ;

Azim, Hatem A., Jr. ;

Piccart, Martine .

NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (01) :27-41

[59] Biomarkers of Response and Resistance to DNA Repair Targeted Therapies [J].

Stover, Elizabeth H. ;

Konstantinopoulos, Panagiotis A. ;

Matulonis, Ursula A. ;

Swisher, Elizabeth M. .

CLINICAL CANCER RESEARCH, 2016, 22 (23) :5651-5660

[60]

Tarapchak P., 2017, ONCOLOGY TIMES

← 1 2 3 4 5 6 7 8 →